GSK receives Priority Review from FDA for dabrafenib/trametinib combination in metastatic melanoma

GlaxoSmithKline plc (LSE:GSK) today announced that the US Food and Drug Administration (FDA) has granted Priority Review designation to its supplemental New Drug Applications (sNDAs) for combined use of Tafinlar® (dabrafenib) and Mekinist® (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 E or K mutation
Source: GSK news - Category: Pharmaceuticals Source Type: news